Strong sales growth during April; Zinzino based revenue increased 36% and the total group revenue with a total of 29% compared with the previous year.
The revenue for Zinzino’s sales markets increased by 36% to SEK 53.4 (39.4) million due to strong growth foremost in Central Europe. Faun Pharma’s external sales decreased by 8% and amounted to SEK 6.1 (6.6) million. Overall, the Group increased revenues by 29 % to SEK 59.5 (46.0) million compared with the previous year.
Accumulated income January – April increased by 24% to SEK 227.7 (183.7) million compared with the previous year.